12:00 AM
Jan 30, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AMG 386: Suspended Phase III enrollment

Amgen suspended enrollment in the double-blind, placebo-controlled Phase III TRINOVA-2 trial evaluating doxorubicin with and without AMG 386 due to supply issues of doxorubicin. The trial planned to enroll about 380 patients. The Phase III TRINOVA-1 trial comparing weekly IV AMG 386 plus paclitaxel vs. placebo plus paclitaxel in...

Read the full 223 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >